We need better tools to control pharma prices

With many drug makers facing no competition, the market isn't working

FROM THE BEGINNING of the Baker-Polito Administration, managing MassHealth has been a top priority.  We are pleased with the progress made to date, including its first major systems overhaul in 20 years, implementing strong internal controls, and reducing the growth rate from double digit numbers. However, it is evident that additional major structural reforms are(...)

Read More »